Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
NCT03519256 · Bristol-Myers Squibb · PHASE2 · terminated · last registry update 2023-06-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient Enrollment” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-21Phase 3 first posted: National Cancer Institute (NCI), Doxorubicin + Pembrolizumab (NCT06422806)
- 2024-05-20Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + sac-TMT (NCT06422143)
- 2024-05-01Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Sacituzumab tirumotecan (NCT06393374)
- 2024-04-23Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab (NCT02775851)
- 2024-04-10Phase 3 first posted: AstraZeneca, Datopotamab Deruxtecan + Rilvegostomig (NCT06357533)
- 2024-04-04Phase 3 first posted: Samsung Bioepis Co., Ltd., SB27 + Keytruda (NCT06348199)
- 2024-04-03Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + Pembrolizumab (NCT06345729)
- 2024-03-15Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06312137)
- 2024-03-06Phase 3 first posted: Inhibrx Biosciences, Inc, INBRX-106 + Pembrolizumab (NCT06295731)
- 2024-02-28Phase 3 first posted: Jazz Pharmaceuticals, Zanidatamab + Cisplatin (NCT06282575)
- 2024-02-07Phase 3 first posted: Regeneron Pharmaceuticals, fianlimab + cemiplimab (NCT06246916)
- 2024-02-01Results posted on the registry: City of Hope Medical Center, Pembrolizumab + Vorinostat (NCT03150329)
- 2024-02-01Phase 3 first posted: AbbVie, Livmoniplimab + Budigalimab (NCT06236438)
- 2024-01-22Phase 3 first posted: NovoCure GmbH, Pembrolizumab + Platinum based chemotherapy (NCT06216301)
- 2023-12-14Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06170788)
- 2023-11-21Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab (NCT03698019)
- 2023-11-07Phase 3 first posted: Eli Lilly and Company, LY3537982 + Pembrolizumab (NCT06119581)
- 2023-11-01Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06112379)
- 2023-10-24Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Nab-paclitaxel (NCT06096844)
- 2023-08-21Phase 3 first posted: Fudan University, Camrelizumab Plus Chemotherapy and Famitinib + Camrelizumab Plus Chemotherapy (NCT05999149)
- 2023-06-27Phase 3 first posted: Amgen, Sotorasib + Pembrolizumab (NCT05920356)
- 2023-06-06Results posted on the registry: Massachusetts General Hospital, Pembrolizumab (NCT03279692)
- 2023-03-23Results posted on the registry: City of Hope Medical Center, Cyclophosphamide + Cytokine-based Biologic Agent IRX-2 (NCT03918499)
- 2022-12-01Phase 3 first posted: Gilead Sciences, Sacituzumab govitecan-hziy (SG) + Pembrolizumab (NCT05633654)
- 2022-11-08Phase 3 first posted: Regeneron Pharmaceuticals, Fianlimab + Cemiplimab (NCT05608291)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision